Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript [Seeking Alpha]
Structure Therapeutics Inc. (GPCR)
Company Research
Source: Seeking Alpha
Company Participants Raymond Stevens - CEO & Director Blai Coll - Chief Medical Officer Conference Call Participants Corey Davis - Lifesci Advisors, LLC Yasmeen Rahimi - Piper Sandler & Co., Research Division Evan Seigerman - BMO Capital Markets Equity Research Seamus Fernandez - Guggenheim Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Terence Flynn - Morgan Stanley, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Samantha Semenkow - Citigroup Inc., Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Jiale Song - Jefferies LLC, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Jayed Momin - Stifel, Nicolaus & Company, Incorporated, Research Division Hardik Parikh - JPMorgan Chase & Co, Research Division Presentation Operator Good morning, a
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target [Seeking Alpha]Seeking Alpha
- Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Structure Therapeutics (GPCR) had its price target lowered by HC Wainwright from $114.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron [Yahoo! Finance]Yahoo! Finance
GPCR
Sec Filings
- 3/16/26 - Form 8-K
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- GPCR's page on the SEC website